Biodistribution of liposomes and C3 fragments associated with liposomes: evaluation of their relationship.
The biodistribution of liposomes with two different kind phospholipids (hydrogenated egg phosphatidylcholine and egg phosphatidylcholine) plus cholesterol (CHOL) were investigated after intravenous administration to rats. Elimination of liposomes from blood circulation was affected by the lipid composition. It appeared that the inclusion of CHOL in liposomes accelerates the rate of liposome uptake by liver, resulting in rapid elimination of liposomes. The amount of C3 fragments bound to liposomes was quantitatively determined to assess the contribution of the complement system to liposome accumulation into organs and liposome destabilization in vivo and in vitro. The amount of bound C3 fragments was directly proportional to CHOL content, and the amount was also proportional to the CLh, CLs as well as CLrel. This relationship suggests that the complement system is responsible for the elimination of liposomes from blood circulation, presumably as a consequence of opsonization by C3 fragments and assembly of membrane attack complex (MAC) onto liposomes. In addition, substitution of cholesteryl methyl ether into the liposome formulation for CHOL significantly diminished not only the binding of C3 fragments but also the CLh, CLs and CLrel, resulting in increased mean resident time (MRT) of the liposomes. This result suggests that the hydroxyl-group on CHOL is a binding site for C3 fragments on the liposomes and that CHOL in a liposome formulation promotes the accumulation of liposomes into the liver and spleen, probably due to their uptake by phagocytic cells, and impairs the stability of the liposomes in blood circulation, via a mechanism involving the complement system.
Ishida
T
T
Department of Pharmacokinetics and Pharmaceutics, Graduate School of Pharmaceutical Sciences, The University of Tokushima, 1-78-1, Sho-machi, Tokushima 770-8505, Japan.
Kojima
H
H
Harashima
H
H
Kiwada
H
H
D000818:Animals; D002784:Cholesterol / Q000493:pharmacokinetics*; D003167:Complement Activation / Q000187:drug effects* / Q000502:physiology; D015932:Complement C3c / Q000378:metabolism*; D007004:Hypoglycemic Agents / Q000097:blood; D007328:Insulin / Q000097:blood; D008081:Liposomes / Q000493:pharmacokinetics*; D008297:Male; D051381:Rats; D017208:Rats, Wistar
D007004:Hypoglycemic Agents; D007328:Insulin; D008081:Liposomes; D015932:Complement C3c; D002784:Cholesterol